Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Chief Medical Officer | July 19, 2022 | July 21, 2022 |
| NEOGENOMICS INCNEO · Entity 2096 | Director | June 01, 2025 | June 03, 2025 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | EVP, Chief Medical Officer | July 08, 2026 | July 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date July 19, 2022 · Filed July 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,898 |
Last balance in matching sequence
After 2022-07-20 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-07-19 · Grant · Acquired 15,000 · Balance 37,500 F1: Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested. F2: Includes 22,500 restricted stock units. Row 2 · 2022-07-20 · Sale · Disposed 5,602 · Balance 31,898 F3: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer. F2: Includes 22,500 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested.
F2: Includes 22,500 restricted stock units.
F3: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer.
NEOGENOMICS INC
Report date June 01, 2025 · Filed June 03, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 131,023 |
Reported balance
After 2025-06-01 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-06-01 · Exercise / conversion · Acquired 12,254 · Balance 131,023 F1: Due to clerical error, this amendment to Form 4 is being filed to correct the transaction code in the reported transaction. F2: As reported in the original Form 4, reflects the release of restricted stock units that were previously reported on a Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Due to clerical error, this amendment to Form 4 is being filed to correct the transaction code in the reported transaction.
F2: As reported in the original Form 4, reflects the release of restricted stock units that were previously reported on a Form 4.
RIGEL PHARMACEUTICALS INC
Report date July 08, 2026 · Filed July 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,025 |
Reported balance
After 2026-07-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-08 · Grant · Acquired 24,400 · Balance 35,025 F1: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from July 8, 2026, with the first annual vest occurring on July 8, 2027. F2: Amount has been adjusted to reflect the cancellation of 5,750 restricted stock units for no consideration, which is exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d) promulgated under the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from July 8, 2026, with the first annual vest occurring on July 8, 2027.
F2: Amount has been adjusted to reflect the cancellation of 5,750 restricted stock units for no consideration, which is exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d) promulgated under the Securities Exchange Act of 1934, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 11, 2026 01:53 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 24,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003238 · form4.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,025 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from July 8, 2026, with the first annual vest occurring on July 8, 2027. F2 · balance_after: Amount has been adjusted to reflect the cancellation of 5,750 restricted stock units for no consideration, which is exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d) promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 15, 2026 Filed May 20, 2026 00:49 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002531 · form4.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,375 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 22:19 UTC Amendment | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 12,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000132 · wk-form4a_1748989184.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Due to clerical error, this amendment to Form 4 is being filed to correct the transaction code in the reported transaction. F2 · shares: As reported in the original Form 4, reflects the release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 23,077 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000126 · wk-form4_1748981239.xml · derivative · entry 4 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,077 Underlying: Common Stock · 23,077 shares Expires not disclosed F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 16,107 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001077183-25-000126 · wk-form4_1748981239.xml · derivative · entry 3 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,107 Underlying: Common Stock · 16,107 shares Expires 2035-06-01 Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 12,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000126 · wk-form4_1748981239.xml · derivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 12,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000126 · wk-form4_1748981239.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,023 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $18.95 | $0.00 |
DisclosureSEC source: 0000905148-25-001932 · form4.xml · derivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2035-05-23 F3 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001932 · form4.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,625 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. F2 · balance_after: This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| August 10, 2024 Filed Aug 13, 2024 20:24 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000127 · wk-form4_1723580646.xml · derivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,336 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2024 Filed Aug 13, 2024 20:24 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 11,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000127 · wk-form4_1723580646.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 12,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000092 · wk-form4_1717531670.xml · derivative · entry 10 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,254 Underlying: Common Stock · 12,254 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 8,672 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001077183-24-000092 · wk-form4_1717531670.xml · derivative · entry 9 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,672 Underlying: Common Stock · 8,672 shares Expires 2034-06-01 Read SEC document |
| May 25, 2024 Filed May 29, 2024 23:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0000905148-24-001652 · form4.xml · derivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-25 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 25, 2024 Filed May 29, 2024 23:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001652 · form4.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,250 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:41 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000121 · wk-form4_1692049280.xml · derivative · entry 8 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,336 Underlying: Common Stock · 11,336 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:41 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 8,353 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001077183-23-000121 · wk-form4_1692049280.xml · derivative · entry 7 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 8,353 shares Expires 2033-08-10 Read SEC document |
| May 26, 2023 Filed Jul 12, 2023 22:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001140361-23-034282 · form4.xml · derivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-26 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 26, 2023 Filed Jul 12, 2023 22:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-034282 · form4.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,250 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:09 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 5,602 | $1.42 | $7,965.48 |
DisclosureSEC source: 0001567619-22-014297 · doc1.xml · nonDerivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,898 F3 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer. F2 · balance_after: Includes 22,500 restricted stock units. Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 20:09 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-014297 · doc1.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 F1 · kind: Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested. F2 · balance_after: Includes 22,500 restricted stock units. Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 00:42 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 13,882 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001077183-22-000110 · wf-form4_165525372464364.xml · derivative · entry 6 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,882 Underlying: Common Stock · 13,882 shares Expires 2029-06-10 Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 00:42 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 15,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000110 · wf-form4_165525372464364.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,433 Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001140361-22-020304 · form4.xml · derivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-05-20 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-020304 · form4.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 21:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001567619-22-002523 · doc1.xml · derivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2032-02-01 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 21:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-002523 · doc1.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on March 15 of each year, with the first 1/4th vesting on March 15, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 22,500 RSUs. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 20:24 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantPerformance Stock Units (PSUs) · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-018716 · doc1.xml · derivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date. F2 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date. F2 · derivative.expiration_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 20:24 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001567619-21-018716 · doc1.xml · derivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-10-23 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from October 24, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 00:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 3,714 | $0.00 Strike: $40.90 | $0.00 |
DisclosureSEC source: 0001077183-21-000162 · wf-form4_162285118004344.xml · derivative · entry 5 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,714 Underlying: Common Stock · 3,714 shares Expires 2028-06-02 Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 00:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 3,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000162 · wf-form4_162285118004344.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,877 Read SEC document |
| May 19, 2021 Filed May 22, 2021 01:11 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001179110-21-005772 · edgar.xml · derivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-05-19 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 19, 2021 Filed May 22, 2021 01:11 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005772 · edgar.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 14, 2021 Filed May 18, 2021 23:01 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001179110-21-005550 · edgar.xml · derivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: The option shall vest in equal monthly installments over the shorter of three years from the date of grant or the period beginning on the date the Reporting Person was appointed to the Company's Board of Directors and ending on the date of the annual meeting at which the Reporting Person is first considered for election by the stockholders, provided that the Reporting Person continues to provide service. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:00 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $7.85 | $0.00 |
DisclosureSEC source: 0001567619-21-005398 · doc1.xml · derivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 26, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 22:22 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001077183-20-000181 · wf-form4_159709812032905.xml · derivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On May 25, 2017, Alison Hannah was granted 10,000 stock options. The options vested ratably on the next three anniversary dates of the grant date. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 22:22 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 10,000 | $7.27 | $72,700.00 |
DisclosureSEC source: 0001077183-20-000181 · wf-form4_159709812032905.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 23:38 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Options (Right to Buy) · Derivative | 3,448 | $0.00 Strike: $28.54 | $0.00 |
DisclosureSEC source: 0001077183-20-000135 · wf-form4_159105466369083.xml · derivative · entry 5 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,448 Underlying: Common Stock · 3,448 shares Expires 2027-05-28 Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 23:38 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 2,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000135 · wf-form4_159105466369083.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,796 Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 20:44 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $7.71 | $0.00 |
DisclosureSEC source: 0001567619-20-002230 · doc1.xml · derivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-02-02 F1 · derivative.exercise_date: The shares subject to the Inducement Option Award will vest and become exercisable as to 25% of the total number of shares subject to the option on February 3, 2021 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 00:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,333 | $9.11 Strike: $9.11 | $75,913.63 |
DisclosureSEC source: 0001077183-19-000168 · wf-form4_156824638474713.xml · derivative · entry 4 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,333 shares Expires 2021-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On July 28, 2016, Alison Hannah was granted 8,333 stock options. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 00:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,333 | $6.66 Strike: $6.66 | $22,197.78 |
DisclosureSEC source: 0001077183-19-000168 · wf-form4_156824638474713.xml · derivative · entry 3 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2020-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On July 15, 2015 Alison Hannah was granted 10,000 stock options, the options vest ratably on the next three anniversary dates of the grant date. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 00:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 8,333 | $9.11 | $75,913.63 |
DisclosureSEC source: 0001077183-19-000168 · wf-form4_156824638474713.xml · nonDerivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 00:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 3,333 | $6.66 | $22,197.78 |
DisclosureSEC source: 0001077183-19-000168 · wf-form4_156824638474713.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Options (Right to Buy) · Derivative | 4,269 | $0.00 Strike: $22.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000108 · wf-form4_156021573544544.xml · derivative · entry 6 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,269 Underlying: Common Stock · 4,269 shares Expires 2026-06-06 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 3,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000108 · wf-form4_156021573544544.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,432 Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:44 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 3,017 | $0.00 Strike: $11.60 | $0.00 |
DisclosureSEC source: 0001077183-18-000043 · wf-form4_152823502163988.xml · derivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,017 Underlying: Common Stock · 3,017 shares Expires 2023-06-01 Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:44 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 15,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000043 · wf-form4_152823502163988.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,013 Read SEC document |
| August 09, 2017 Filed Oct 3, 2017 21:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option (Right to Buy) · Derivative | 6,667 | $6.66 Strike: $6.66 | $44,402.22 |
DisclosureSEC source: 0001209191-17-055258 · doc4.xml · derivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 6,667 shares Expires 2020-07-15 F1 · derivative.exercise_date: On July 15, 2015 Alison Hannah was granted 10,000 stock options, the options vest ratably on the next three anniversary dates of the grant date. On 8/9/2017 6,667 of these options were exercised leaving a balance of 3,333. Read SEC document |
| August 09, 2017 Filed Oct 3, 2017 21:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 6,667 | $6.66 | $44,402.22 |
DisclosureSEC source: 0001209191-17-055258 · doc4.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.